In January 2006, a clinical announcement made by the National Cancer Institute suggested that intraperitoneal chemotherapy become standard care for patients with newly diagnosed stage III, optimally debulked epithelial ovarian cancer. Intraperitoneal chemotherapy is new to many healthcare providers (i.e., physicians, nurses, and pharmacists). This article will discuss how to implement intraperitoneal chemotherapy in practice. Education and experience are the keys to successful implementation.
Armstrong, D.K., Bundy, B., Wenzel, L., Huang, H.Q. Baergen, R., Lele, S., et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. <i>New England Journal of Medicine</i>, 354, 34-43.
Davidson, S.A., Rubin, S.C., Markman, M., Jones, W.B., Hakes, T.B., Reichman, B., et al. (1991). Intraperitoneal therapy: Analysis of complications with an implanted subcutaneous port and catheter system. <i>Gynecologic Oncology</i>, 41, 101-106.
Dedrick, R.L., Myers, C.E., Bungay, P.M., & DeVita, V.T., Jr. (1978). Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. <i>Cancer Treatment Reports</i>, 62, 1-11.
Makhija, S., Leitao, M., Sabbatini, P., Bellin, N., Almadrones, L., Leon, L., et al. (2001). Complications associated with intraperitoneal chemotherapy catheters. <i>Gynecologic Oncology</i>, 81, 77-81.
Markman, M., & Walker, J.L. (2006). Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. <i>Journal of Clinical Oncology</i>, 24, 988-994.
National Cancer Institute. (2006). NCI announcement on intraperitoneal cancer therapy for ovarian cancer. Retrieved March 2, 2007, from <a target="_blank" href='http://www.cancer.gov/clinicaltrials/developments/IPchemo-digest'>http:/...
Walker, J.L., Armstrong, D.K., Huang, H.Q., Fowler, J., Webster, K., Burger, R.A., et al. (2006). Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian or primary peritoneal cancer. A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i>, 100, 27-32.
Weisberger, A.S., Levine, B., & Storaasli, J.P. (1955). Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. <i>JAMA</i>, 159, 1704-1707.